… No in¬ creased adverse effects were demonstrated with in¬ creased antigen content in the
acellular vaccine formu¬ lations. The APV formulation is currently part of the second efficacy …

… B pertussis antigens (pertussis toxin, filamentous hemagglutinin, and pertactin). Antibody titers
against pertussis … Results: A CMI-positive response to at least 1 B pertussis antigen at 1 or …

… populations against pertussis is generally achieved through administration of a single dose
of reduced antigen content combined diphtheria and tetanus toxoids and acellular pertussis (…

… that PTd was the essential antigen in the acellular pertussis vaccine but that fFHA … content
in the vaccine may be reduced by adding fFHA to get the same ED50, but total protein content …

… immunogens in OMVs together with a variety of putatively important antigens. The structure
… antigens, each of which may be insufficient to confer immunity when administered alone. …

… reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered
as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine. …

… To our knowledge, this is the first study exploring the feasibility of repeated decennial booster
vaccination with reduced-antigen-content acellular pertussis vaccines in adults. The adults …

… In order to address the issue of optimal antigen content of acellular pertussis … acellular DTP
vaccine in two dosage regimens in children 15-24 months and 4-6 years of age. The acellular …

… #icacy of acellular pertussis vaccines. The reactogenicity and immunogenicity results of the
various Phase II trials in which acellular vaccines with widely di#erent antigen contents have …

… reactogenicity of whole-cell pertussis vaccines when administered beyond childhood. …
acellular pertussis vaccines with reduced antigen content has seen calls for widespread pertussis …